Affidea Nu-med Center of Oncological DIagnostics and Therapy
Zamość, Lublin Voivodeship
What changed
Study registered, no phase assigned: Reirradiation and Total Ablative Strategies for Recurrent Gynecologic Cancer
3w agoTrial registeredJun 24, 2026Source filing (opens the source filing in a new tab)
Momentum
Momentum 70 out of 100, unchanged since the last recompute.
Accelerating: several high-weight events landed recently.
Runway (estimate)
No disclosed raise on file, so there is nothing to model from.
Stage
Grant-only
The furthest-along thing in the public record. Not a projection.
Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.
Grant to raise
Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.
- Trial
Study registered
Jun 11, 2026Recurrent Gynecologic Cancer, Recurrent Uterine Cancer, Recurrent Cervical Cancer, Recurrent Vaginal Cancer, Recurrent Vulvar Cancer, Recurrent Ovarian Cancer, Recurrent Fallopian Tube Cancer, Primary Peritoneal Cancer · RECRUITING · sponsor: Affidea Nu-med Center of Oncological DIagnostics and Therapy · Reirradiation and Total Ablative Strategies for Recurrent Gynecologic Cancer
ClinicalTrials.gov · NCT07667192 (opens the source filing in a new tab)
Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources